Answers are grounded in this paper and cite their sources.
Background: Piperacillin-tazobactam (TZP) is widely utilized for the empirical treatment of severe infections, with an increasing prevalence of resistance in clinical settings. Thus, this study aimed to evaluate TZP resistance patterns and associated factors across various clinical samples. Methods: This retrospective cross-sectional study was conducted using recorded laboratory data from the Pathology Center for Diagnosis and Research (PCDR), Faculty of Medicine, University of Gezira, Wad Medani, Sudan, covering the period from January 2020 to October 2023. Results: Over the 4 years, 265 samples were tested for TZP resistance. The overall resistance rate was 34% (90/265). Seven types of isolated bacteria were examined; the majority, 211 (79.6%), were Gram-negative bacteria. The highest proportion of TZP resistance rate was observed in Escherichia coli, 45.5% (50/110), and Klebsiella spp., 28.6% (4/14). Most of the studied samples were from wound swabs, 54.3% (144), of which 45.1% (65) had the highest resistance rate. A statistically significant association was observed between TZP resistance and gender (P = 0.023), year (P = 0.033), and type of Gram stain reaction (P = 0.041). Conclusion: This study reported a moderate rate of resistance for TZP, with the highest rate of resistance found in E. coli and wound swabs. The TZP resistance rate was significantly correlated with gender, year, type of Gram stain reaction, type of isolated bacteria, and type of clinical specimen. Therefore, a targeted and robust educational campaign should be implemented to help reduce the rate of TZP resistance.
No takes yet. Share an insight, caveat, or question.
Hamadalneel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: